All In Biotech

Drug Trial Radar · NCT06936527

XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

An Open-label, Multicenter Phase Ib/II Clinical Study: Aim to Valuate the Efficacy and Safety of XS-03 Comination With FOLFOX or FOLFIRI and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

102

Planned (sponsor's estimate)

Start

May 23, 2025

Primary completion

Apr 30, 2028

Study completion Jul 30, 2028

Sponsor

Sponsor type
Industry
First posted
Apr 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation

Conditions

  • Colorectal Cancer
  • Metastatic Colorectal Cancer With RAS Mutation

Interventions

  • Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRIBiological

    XS-03 orally Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously

  • Drug: XS-03Biological

    XS-03 orally

  • Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRIBiological

    Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of participants with Dose-limiting Toxicities (DLTs) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and BevacizumabTime frame: up to day 28
  2. Phase 1b: Determine the Maximum Tolerated Dose (MTD) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and BevacizumabTime frame: up to day 28
  3. Phase 2: Objective Response Rate (ORR) of two experimental arms and comparator armTime frame: up to 18 months after first dose of last patient

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.